IVVD (Invivyd, Inc.) Stock Financials & Earnings | Market Cap Arena

IVVD (Invivyd, Inc.) Stock Financials & Earnings | Market Cap Arena

IVVDInvivyd, Inc.

Mkt Cap$257M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$53M

Net Income (TTM)-$52M

EPS (TTM)-$0.38

Free Cash Flow (TTM)-$58M

Gross Margin93.0%

Op. Margin-104.0%

Net Margin-98.2%

FCF Margin-109.1%

P/S Ratio (TTM)4.8x

P/E Ratio (TTM)—

YoY Rev Growth+110.5%

Employees—

Earnings Reports

Next: Q1 2026 · Mar 19

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$0	$0	-$39M
Q2 23	$0	$0	-$54M
Q3 23	$0	$0	-$43M
Q4 23	$0	$0	-$77M
Q1 24	$0	$0	-$46M
Q2 24	$2M	$2M	-$49M
Q3 24	$9M	$8M	-$62M
Q4 24	$14M	$13M	-$19M
Q1 25	$11M	$10M	-$17M
Q2 25	$12M	$11M	-$15M
Q3 25	$13M	$12M	-$11M
Q4 25	$17M	$16M	-$13M

Valuation

Quarter	P/S	P/E
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q1 24	—	—
Q2 24	113.7x	—
Q3 24	22.3x	—
Q4 24	10.1x	—
Q1 25	7.0x	—
Q2 25	5.6x	—
Q3 25	5.1x	—
Q4 25	4.8x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$41M	-$42M
Q2 23	-$37M	-$37M
Q3 23	-$35M	-$35M
Q4 23	-$59M	-$59M
Q1 24	-$50M	-$50M
Q2 24	-$42M	-$42M
Q3 24	-$41M	-$41M
Q4 24	-$38M	-$38M
Q1 25	-$21M	-$21M
Q2 25	-$13M	-$13M
Q3 25	-$8M	-$8M
Q4 25	-$15M	-$15M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$624K
Q2 23	$9K
Q3 23	$0
Q4 23	$0
Q1 24	$140K
Q2 24	$0
Q3 24	$5K
Q4 24	$5K
Q1 25	$144K
Q2 25	$11K
Q3 25	$0
Q4 25	$0

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	—	-61.2%
Q2 23	—	+4.1%
Q3 23	—	-9.0%
Q4 23	—	+59.2%
Q1 24	—	+18.0%
Q2 24	—	-4.4%
Q3 24	—	+66.3%
Q4 24	—	-56.9%
Q1 25	—	-38.8%
Q2 25	+420.6%	-47.9%
Q3 25	+41.2%	-66.3%
Q4 25	+24.5%	-9.9%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$5M	—
Q2 23	$5M	—
Q3 23	$4M	—
Q4 23	$4M	—
Q1 24	$5M	—
Q2 24	$8M	375.0%
Q3 24	$3M	30.8%
Q4 24	$3M	22.1%
Q1 25	$3M	25.0%
Q2 25	$3M	27.0%
Q3 25	$3M	23.4%
Q4 25	$3M	14.9%

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 23	$27M	$11M	—
Q2 23	$44M	$10M	—
Q3 23	$26M	$13M	—
Q4 23	$62M	$15M	—
Q1 24	$31M	$15M	—
Q2 24	$30M	$21M	—
Q3 24	$58M	$13M	—
Q4 24	$18M	$14M	—
Q1 25	$11M	$17M	—
Q2 25	$10M	$17M	—
Q3 25	$8M	$15M	—
Q4 25	$10M	—	$19M

Revenue Segments

Quarter	Product
Q2 24	$2M
Q3 24	$9M
Q4 24	$14M
Q1 25	$11M
Q2 25	$12M
Q3 25	$13M
Q4 25	$17M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$126M	$207M	$333M
Q2 23	$122M	$176M	$298M
Q3 23	$182M	$83M	$265M
Q4 23	$201M	$0	$201M
Q1 24	$189M	$0	$189M
Q2 24	$148M	$0	$148M
Q3 24	$107M	$0	$107M
Q4 24	$69M	$0	$69M
Q1 25	$48M	$0	$48M
Q2 25	$35M	$0	$35M
Q3 25	$85M	$0	$85M
Q4 25	$227M	$0	$227M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	109M	-0.2%
Q2 23	109M	+0.6%
Q3 23	110M	+0.3%
Q4 23	110M	+0.1%
Q1 24	116M	+5.2%
Q2 24	119M	+3.2%
Q3 24	119M	+0.1%
Q4 24	119M	-0.8%
Q1 25	120M	+1.1%
Q2 25	120M	+0.1%
Q3 25	170M	+41.8%
Q4 25	172M	+1.2%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 20	—	—
FY 21	$0	101
FY 22	$0	100
FY 23	$0	94
FY 24	$256K	99
FY 25	$438K	122